WHAT IS CLAIMED IS:

1. Use of cyclic Glycine Proline (cGP) in the manufacture of a composition for ameliorating the effects of and/or treating peripheral neuropathy in a subject.
2. The use as claimed in claim 1, wherein the peripheral neuropathy is type 2 diabetes-associated peripheral neuropathy.
3. The use as claimed in claim 1 or claim 2, wherein the composition is formulated for oral administration.
4. The use as claimed in any one of the preceding claims, wherein the composition is formulated as a pill, tablet, capsule, liquid, powder, micronized powder, gel, soft gel full of liquid and/or combinations thereof.
5. The use as claimed in claim 4, wherein the micronized powder particle size is substantially between 1 to 1000 micron.
6. The use as claimed in any one of the preceding claims, wherein the composition is formulated for administration so as to provide a therapeutically effective dose of cGP of at least between 10,000 to 100,000 ng (10-100 µg) as daily dose.
7. The use as claimed in claim 6, wherein the composition is formulated for administration so as to provide a therapeutically effective dose of cGP of between 20-40 µg as daily dose.
8. The use as claimed in any one of the preceding claims, wherein the cGP is derived from any animal, marine and/or fungal sources.
9. The use as claimed in claim 8, wherein the sources comprise bovine, marine and bone collagen sources.
10. The use as claimed in claim 8 or 9, wherein the cGP is formed by hydrolysation of collagen or gelatin proteins to form linear peptides with repeated sequences of hydrolysed proline-glycine, wherein cyclisation of the linear peptides leads to production of cGP.
11. The use as claimed in any one of claims 8 to 10, wherein the cGP is formed by hydrolysation of bovine collagen powder, collagen marine skin powder, fish skin powder and/or bone collagen.
12. The use as claimed in in any one of claims 8 to 10, wherein the cGP is formed from body parts selected from: skins, proteins, bones, muscles tendons and/or combinations thereof.
13. The use as claimed in in any one of claims 8 to 10, wherein the cGP is formed by maceration of animal, marine and/or fungal material, followed by drying to form a micronized powder.
14. The use as claimed in claim 13, wherein the micronized powder is encapsulated within soft gels and/or hard shells.

15. The use as claimed in claim 14, wherein the soft gels and/or hard shells comprise gelatin.

16. The use as claimed in claim 15, wherein the cGP concentration increases over time.

17. The use as claimed in claim 16, wherein the increase is from 0.1ng/mg to 10ng/mg.